Targeted therapy for advanced bone cancer with an ALK gene change
Treatments studied
Part of Bones, joints & muscles, Cancer clinical trials.
This study tests two targeted pills, crizotinib and alectinib, for people with advanced bone cancer that has a specific gene change called ALK. These medicines block the ALK protein, which may help shrink or slow the cancer if standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 20 years old.
- Your cancer is advanced or has spread, and it has an ALK gene change.
- Your cancer has gotten worse during or soon after standard treatment, or no standard treatment is available.
- You have at least one tumor that can be measured on scans.
- You are generally well enough to care for yourself (ECOG score 0–2) and expected to live at least 8 weeks.
- You have not had radiation within the past 2 weeks and do not have brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
This early-phase trial studies how alectinib (an ALK-blocking medicine) moves through the body and how it’s tolerated in people with advanced non-small cell lung cancer (NSCLC) that has an ALK rearrangement. You may be considered if you have ALK-positive, recurrent or advanced disease and have already had specific prior treatments.
This study tests whether alectinib can treat ALK-positive cancers in adults, teenagers, and children. It focuses on people whose cancer testing shows an ALK change, and who can start oral treatment and have a new tissue sample.
This study tests a new pill (SY-3505) compared to the standard first treatment (crizotinib) for people with ALK-positive advanced lung cancer that hasn't been treated yet. If you qualify, you'd be randomly assigned to one of these two oral medicines, and the study will see which one works better.
This trial tests combining the targeted pill alectinib with chemotherapy before the main treatment for stage III ALK-positive lung cancer that can't be removed surgically. The goal is to see if this combo shrinks the tumor and improves outcomes.
This trial tests giving alectinib first, then adding targeted radiation to remaining spots of cancer in people with ALK-rearranged advanced non-small cell lung cancer. It aims to control the cancer after an initial response and help keep disease from progressing.
Hear when a new Bone Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.